Competitive intelligence on every rival trial, readout and approval, in a sourced brief every Monday
Every rival trial, readout and approval lands in a sourced brief for each programme, every Monday.
See one case, screen by screen ↓A programme team needs to know when a rival’s trial changes phase, a pivotal study reads out or an agency approves a medicine in its indication. Today that knowledge is assembled by hand: an analyst checks trial registries record by record, reads newsrooms and pipeline pages, searches congress abstracts and agency databases, then rebuilds the landscape deck.
The same event turns up three times — in the registry, the press release and the abstract — and has to be merged before anyone can say whether it matters for our programme. By the time the deck reaches the team, the landscape has moved, and the numbers in it are hard to trace back to the page they came from.
Estimated split of the 9-day median by hand (2025) and the 3-day target with the solution. Most of what is left is the wait for the Monday run — approvals and pivotal readouts reach the team the same day.
Six specialist agents watch, compare and write up every change; an analyst approves each brief.
Week 40 for the KRAS G12D programme team: a rival medicine is approved in pancreatic cancer, another enters Phase 3 in the indication we plan for, and a lung cancer combination reads out. Here is the morning, screen by screen, in the working solution.
Lena opens the solution to a finished watch run: 1,284 sources checked for 42 rival assets across four watch lists — 23 changes, 5 that matter. Two briefs wait for her approval, due to their teams by 12:00, and two changes about sites on the feasibility shortlist wait for her to confirm. Sam Patel has already sent the Claudin 18.2 brief to 11 people at 08:35.
This morning’s watch run: “Change detector — 29 findings → 23 changes.”
Oncology — KRAS holds 14 watched assets from 11 sponsors, set out by mechanism — G12C, G12D, pan-RAS, other alleles, pathway partners — and by phase. Our programme NX-4127 sits in Phase 2; two rivals are approved and two are in Phase 3 ahead of it. Assets that changed this week are marked, and the three significant changes are listed beside the matrix.
The run is shown step by step. The Registry watcher checks 4 trial registries for the 14 assets; the News watcher reads 38 press releases and pipeline pages; the Abstract reader goes through 212 congress abstracts and matches the late-breaker LBA-71 to CORAL-301; the Approval watcher finds a new US approval for VNT-224. The Change detector merges 14 findings into 11 changes, and the Brief writer drafts the KRAS brief. The last step waits for the analyst.
“11 changes found · 3 significant. VNT-224 approved in the US · CORAL-301 met its endpoint · SLN-0582 entered Phase 3. Every change is linked to its source.”
The change feed shows what moved since the last capture on Mon 28 Sep: status from “Under review (priority)” to “Approved — United States”, indication 2L+ metastatic PDAC, KRAS G12-mutant, label test-selected with overall survival 12.4 vs 6.8 months. Beside it, the agency approval letter and Vantor Pharma’s press release, each with the exact sentence highlighted.
Why it matters for NX-4127: “It sits in the same second-line population as our NX-4127 Phase 2, and becomes the treatment our next trial is likely to be compared with.”
SOLSTICE-PANC is registered: SLN-0582 moves from Phase 2 to Phase 3 in first-line metastatic PDAC, NCT07214863, an estimated 540 patients, 210 planned sites in 19 countries. The Change detector explains why it matters — Solenne is about 12–18 months ahead, and 38 of its likely sites are on our feasibility shortlist — and proposes it as significant. Lena confirms it, or marks it not significant.
Significant changes need an analyst’s confirmation; anything below 85 % confidence goes to review.
The KRAS landscape brief for week 40 opens with a three-point bottom line, then what changed — the VNT-224 approval, the SOLSTICE-PANC phase advance, the CORAL-301 readout — each with a “So what” for NX-4127. The sources panel shows 14 of 14 claims sourced, numbers matching the sources, one page. Click any number in the brief to open its passage.
The brief turns the week into three actions: review the second-line Phase 3 design with VNT-224 as the likely comparator before the 2 Nov governance meeting (Priya Raman, clinical development); check the 38 shared sites before site selection closes on 30 Oct (Jonas Weber, clinical operations); update the target product profile with the 12.4-month benchmark (Dr. Maya Chen). Eight smaller changes follow under “Also this week”.
The Brief writer’s rules: every claim needs a source passage; no forecasts stated as fact.
The approval screen shows 14 of 14 claims linked, the 14 readers, from the programme lead to regulatory and market access, and how it goes out — email with the brief as a PDF, and a post to the programme page. One change, PLH-12, is still unconfirmed; the screen says so, and that approving the brief confirms it as written.
“Your approval is recorded with your name and the time, and the sent version is kept.”
The brief moves to Sent and the activity trail reads in order: the Change detector found 11 changes, the Brief writer drafted the brief with 14 claims, Lena confirmed 9 of 11 changes, confirmed PLH-12 with the brief, and approved and sent it to 14 people.
280 changes detected across 42 watched assets, 45 significant — each confirmed by an analyst — and 46 briefs sent to 4 programme teams. Event to programme team: a median of 3.2 days, against 9 by hand. By watch list, briefs on time and analyst edits per brief; by source, where the changes came from.
The same Monday, seen by the people who write, approve and read the brief — what their week looked like, and what it looks like now.
Six specialist agents watch, compare and write up every change; an analyst approves each brief.
Checks trial registries every week for each watched asset and records what changed in each trial record — status, phase, enrolment, dates, arms, sites — with the exact text before and after.
Reads company press releases and pipeline pages and captures pipeline moves, filings and topline results for watched sponsors.
Reads congress abstracts and pulls design, population, endpoints (PFS, OS, ORR, DoR) with confidence intervals and grade ≥ 3 adverse events into a comparable table.
Checks agency approval databases in the US, EU and Japan for approvals, filing acceptances and label changes.
Merges what the watchers found — one real-world event is one change, even when seen in three sources — scores significance with the watch list’s rules and explains in two sentences why it matters to our programme.
Writes the one-page weekly brief for each programme team — bottom line, what changed, what it means with a suggested owner, also this week, watch next — with every claim linked to its source passage.
Approves before anything is sent. The agents propose; a named person decides.
Ask about any rival asset, change or brief — or tell it what to watch. Every answer links to its sources.
What changed for KRAS this week?
This morning’s run found 11 changes across the 14 KRAS assets — 3 matter for NX-4127: the VNT-224 approval in second-line pancreatic cancer, SLN-0582 as the first G12D-selective medicine in Phase 3 in first-line PDAC, and the KST-907 Phase 3 readout in first-line lung cancer (HR 0.64). The other 8 are registry and pipeline updates, all in this week’s brief.
How does the VNT-224 approval affect NX-4127?
Three things change. Comparator: a second-line Phase 3 would likely be compared with VNT-224, not chemotherapy. Benchmark: median OS to beat in second line is now 12.4 months (HR 0.46 vs chemotherapy). Timing: first line is still open — VNT-224 is approved only after prior therapy, and SLN-0582’s first-line trial reads out around mid-2029.
Which of our sites overlap with competitor trials?
41 sites on the NX-4127 feasibility shortlist also appear in competitor KRAS trials: 38 in SOLSTICE-PANC (SLN-0582) and 3 in PELL-12-101 (PLH-12). SOLSTICE-PANC is the one to watch — it is not yet recruiting, so our site selection, closing 30 Oct, can still move first.
Alert me the same day when a rival KRAS trial is stopped
Done. A new rule under “What counts as significant”: a watched trial is suspended, terminated or withdrawn — with a same-day alert to you and Sam Patel, outside the weekly brief. It would have fired once in the last 12 weeks, when MRL-209 was suspended on 23 Sep. The change is saved as a new version of the watch settings and is on the audit trail.
12 screens from the working solution, on its sample data. Pick one to see it large.
What to watch, when, who approves and what counts as significant are settings — each change saved as a new version and recorded in the audit trail.
| Setting | Default | Choose from |
|---|---|---|
| Watch run | Every Monday, 06:00 CET | Every Monday, 06:00 CET · Every Monday and Thursday, 06:00 CET · Every day, 06:00 CET |
| Brief delivery | As soon as it is approved | As soon as it is approved · Monday 12:00, if approved |
| Same-day alerts for approvals and pivotal readouts | On | On · Off |
| Approver for each watch list | Lena Ortiz (KRAS, TL1A) · Sam Patel (Claudin 18.2, Lp(a)) | Lena Ortiz · Sam Patel |
| Significant: approval, filing acceptance or label change; pivotal readout or topline result; phase advance | On | On · Off, per rule |
| Significant: new trial in our indication; sites added in our shortlist countries | On | On · Off, per rule |
| Significant: trial stopped, suspended or terminated; primary completion moves more than 3 months | Off — a stopped trial is reported in the weekly brief | On · Off, per rule |
| Watch lists | 4 lists · 42 assets | Add a watch list or an asset |
Every figure is labelled: a target the solution is built to, an estimate, a typical published result, or a proven one.
“demo” = seen in the working solution, on its sample landscape · “target” = the design goal, measured in the live solution · “estimated” = our estimate · by-hand figures are the 2025 analyst workload baseline shown in the solution. People, companies, assets and trials named on this page are characters and sample data in the working solution.
A competitive intelligence solution for drug development programmes. Six agents watch trial registries, company press releases and pipeline pages, congress abstracts and agency approval databases for every rival asset on your watch lists, and write a one-page brief for each programme team every Monday. An analyst approves each brief before it is sent.
The Change detector merges what the watchers found into one change per real-world event, then applies your watch list’s rules — approvals and label changes, pivotal readouts, phase advances, new trials in your indication, sites in your shortlist countries — and explains why it matters for your programme. An analyst confirms each significant change; anything below 85 % confidence goes to review.
Public sources only: 4 trial registries (US, EU, Japan, China), press releases and pipeline pages of 126 companies, abstracts from 9 oncology, immunology and cardiology congresses, and agency approval databases in the US, EU and Japan. Each source version is kept, so the record shows what a page said on the day it was captured.
Yes. Every claim links to the exact passage it came from — click a number in the brief to open the registry record, press release, abstract or approval letter at that passage. Numbers are copied from the source, never computed.
No. A brief is sent only after a named analyst approves it, and the approval is recorded with the name and the time. Same-day alerts for approvals and pivotal readouts are confirmed by the analyst too.
Yes. Watch lists, assets, approvers, the watch run schedule, brief delivery, same-day alerts and what counts as significant are all settings. You can also ask in plain words — “alert me the same day when a rival trial is stopped” — and every change is saved as a new version on the audit trail.
The Agentic Solution Engine builds and deploys it from your requirements — your programmes, the rival assets you watch, your brief template and your significance rules — and it goes live once every quality gate has passed. We will walk you through it on one of your own landscapes first.
Ask the literature in plain words and get a sourced answer in seconds.
1-min filmPreclinical ReportsRaw study data becomes a draft report in hours, with every number traced to its source.
1-min filmScience HarvesterEvery inherited file read and cited, and a signed dossier for each asset before the experts leave.
1-min filmWe’ll run Competitive Pipeline Watch on the rivals of one of your own programmes.